LEXARIA BIOSCIENCE CORP. Liabilities Assumed
LEXARIA BIOSCIENCE CORP. (LEXX) reported Liabilities Assumed of $163.97 thousand for the 9-month period ending 2024-05-31, per its 10-Q filed 2024-07-12.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2024-07-12
- LEXARIA BIOSCIENCE CORP. liabilities assumed for the quarter ending 2024-05-31 was $0.00.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 6 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month |
|---|---|---|---|---|
| 2024-05-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-07-12 | $163.97K 10-Q · filed 2024-07-12 | ||
| 2024-02-29 | $163.97K 10-Q · filed 2024-04-09 | |||
| 2023-08-31 | $49.99K 10-Q · filed 2024-07-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |